文献速递痛风与晶体性关节病

痛风临床试验中OMERACT核心域测量时机:随机试验的系统综述

Timing of OMERACT core domain measurement in gout clinical trials: a systematic review of randomised trials.
PubMed 文献 · Semin Arthritis Rheum · 2026-08-18

该系统综述评估了2005年以来29项降尿酸治疗试验和14项痛风发作随机试验中OMERACT核心域的测量时间点和频率及报告完整性。降尿酸治疗试验中核心域测量频率有7种,血清尿酸和痛风发作最常每月测量,痛风石负荷最常每3个月测量;痛风发作试验中有9种频率,疼痛、关节压痛和关节肿胀最常每月测量。全部收集数据的报告率差异大,降尿酸试验从血清尿酸24/29(83%)到活动受限0/2(0%),痛风发作试验从疼痛13/14(93%)到关节压痛3/8(37.5%)。

要点

  • 降尿酸治疗试验中核心域测量频率有7种,血清尿酸和痛风发作最常每月测量。
  • 痛风发作试验中核心域测量频率有9种,疼痛、关节压痛和肿胀最常每月测量。
  • 全部收集数据的报告率差异大,降尿酸试验血清尿酸24/29(83%)至活动受限0/2(0%)。

核心结论

  • 降尿酸治疗和痛风发作试验中核心域测量时机存在显著差异,且收集数据的报告不一致。
  • 该工作为建立OMERACT认可痛风核心域标准化测量时间点和频率的共识过程提供了基础。

研究设计与样本

  • 系统综述,纳入2005年以来降尿酸治疗随机试验29项和痛风发作随机试验14项。
  • 数据提取每个核心域的测量时间点和频率,以及是否报告了所有收集的测量。

主要发现

  • 降尿酸治疗试验中核心域在7种不同频率下测量,血清尿酸和痛风发作最常每月测量,痛风石负荷最常每3个月测量。
  • 痛风发作试验中核心域在9种不同频率下测量,疼痛、关节压痛和关节肿胀最常每月测量。
  • 降尿酸治疗试验中全部收集测量的报告率从血清尿酸24/29(83%)到活动受限0/2(0%)。
  • 痛风发作试验中全部收集测量的报告率从疼痛13/14(93%)到关节压痛3/8(37.5%)。

关键数值与推荐

  • 降尿酸治疗试验:血清尿酸报告率24/29(83%),活动受限报告率0/2(0%)。
  • 痛风发作试验:疼痛报告率13/14(93%),关节压痛报告率3/8(37.5%)。
  • 降尿酸治疗试验中核心域测量频率有7种,痛风发作试验中有9种。

临床怎么用

  • 提示临床医生在解读痛风试验结果时需注意核心域测量时机和报告完整性的差异。
  • 为未来痛风临床试验标准化核心域测量时间点和频率提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The Outcome Measures in Rheumatology (OMERACT) initiative has endorsed core domain sets for gout trials. The aims of this study were to evaluate the time points and frequencies at which the gout core domains are measured in existing gout urate-lowering therapy and gout flare trials, and whether all collected measurements were reported. METHODS: Urate-lowering therapy (n = 29) and gout flare randomised clinical trials (n = 14) from 2005 were identified from a prior systematic review of core domain reporting. Data were extracted for the time points and frequencies at which each core domain was measured, as well as whether all collected measurements were reported. RESULTS: In urate-lowering therapy trials, the core domains were measured at seven different frequencies. Serum urate and gout flares were most commonly measured monthly, and tophus burden was most commonly measured three monthly. Reporting of all collected measurements varied, from 24/29 (83%) trials for serum urate to 0/2 (0%) trials for activity limitation. In gout flare trials, core domains were measured at nine different frequencies. Pain, joint tenderness and joint swelling were most commonly measured monthly. Reporting of all collected measurements varied, from 13/14 (93%) trials for pain to 3/8 (37.5%) trials for joint tenderness. CONCLUSION: In both urate-lowering therapy and gout flare trials, there is substantial variability in when the core domains are measured, and reporting of collected measurements is inconsistent. This work provides the foundation for a consensus process to establish standardised time points and frequencies for measuring the OMERACT-endorsed gout core domains.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Prendergast E, Dalbeth N, Christensen R, et al. Timing of OMERACT core domain measurement in gout clinical trials: a systematic review of randomised trials. Semin Arthritis Rheum. 2026. PMID: 42641197. doi:10.1016/j.semarthrit.2026.153064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。